FDA Warns DrMedHealth Over "Same Active Ingredient as Ozempic" Compounded GLP-1 Claims
On June 8, 2026, FDA issued a warning letter to Public Health Solution LLC dba DrMedHealth after a March 2026 review of drmedhealth.com, which offers compounded semaglutide and tirzepatide products. FDA cites website claims including "Same active ingredient as Ozempic®" and "Same active ingredient as Mounjaro®," saying such claims "represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
Source: FDA original ↗